GLYCOSIDE HYDOLASES AND THEIR USE IN PREVENTING AND/OR TREATING A PATHOGENIC INFECTION IN AN ANIMAL
Disclosed are methods and compositions using glycoside hydrolases, such as an alpha-L-fucosidases, to prevent and/or treat a pathogenic infection and/or diarrhea in an animal wherein the pathogenic infection is caused by a pathogen capable of binding to an animal intestinal cell wherein said binding of the pathogen is dependent on the presence of a pathogen binding site having at least one glycan structure substituted with at least one alpha-1,2-L-fucose moiety comprising administering to the animal an effective amount of a glycoside hydrolase capable of removing the at least one alpha-1,2-L-fucose moiety from the pathogen binding site.
1 . A method for preventing an animal from having an intestinal pathogenic infection and/or diarrhea wherein the pathogenic infection and/or diarrhea is caused by a pathogen capable of binding to an animal intestinal cell wherein said binding of the pathogen is dependent on the presence of a pathogen binding site having at least one glycan structure substituted with at least one alpha-1,2-L-fucose moiety comprising administering to the animal an effective amount of a purified glycoside hydrolase family 95 (GH95) alpha-L-fucosidase capable of removing the at least one alpha-1,2-L-fucose moiety from the pathogen binding site.
2 - 3 . (canceled)
4 . The method of claim 1 wherein the GH95 alpha-L-fucosidase is capable of removing a terminal alpha-1,2-linked fucose group from a glycan-containing structure.
5 . The method of claim 1 wherein the pathogen is Escherichia coli expressing F18 fimbriae.
6 . The method of claim 1 wherein the method further comprises administering to the animal an effective amount of a GH95 alpha-L-fucosidase in combination with at least one direct fed microbial.
7 . The method of claim 6 wherein the method further comprises administering to the animal an effective amount of a GH95 alpha-L-fucosidase in combination with at least one direct fed microbial and at least one protease.
8 . The method of claim 1 wherein the GH95 alpha-L-fucosidase is encapsulated.
9 . The method of claim 6 wherein the GH95 alpha-L-fucosidase is encapsulated.
10 . The method of claim 1 wherein the GH95 alpha-L-fucosidase and/or the direct fed microbial and/or the protease are administered in an animal feed or a premix.
11 . The method of claim 6 wherein the GH95 alpha-L-fucosidase and/or the direct fed microbial and/or the protease are administered in an animal feed or a premix.
12 . The method of claim 1 wherein the GH95 alpha-L-fucosidase is in the form of a granule.
13 . The method of claim 6 wherein the alpha-L-GH95 fucosidase is in the form of a granule.
14 . A composition for preventing an animal having an intestinal pathogenic infection and/or diarrhea wherein the pathogenic infection is caused by a pathogen capable of binding to an animal intestinal cell wherein said binding of the pathogen is dependent on the presence of a pathogen binding site having at least one glycan structure substituted with at least one alpha-1,2-L-fucose moiety comprising administering to the animal an effective amount of a purified glycoside hydrolase family 95 (GH95) alpha-L-fucosidase capable of removing the at least one alpha-1,2-L-fucose moiety from the pathogen binding site.
15 . (canceled)
16 . (canceled)
17 . The composition of claim 14 wherein the GH95 alpha-L-fucosidase is capable of removing a terminal alpha-1,2-linked fucose group from a glycan-containing structure.
18 . The composition of claim 14 wherein the pathogen is Escherichia coli expressing F18 fimbriae.
19 . The composition of claim 14 wherein said composition further comprises at least one direct fed microbial.
20 . The composition of claim 19 wherein said composition further comprises at least one direct fed microbial and at least one protease.
21 . The composition of claim 14 wherein the GH95 alpha-L-fucosidase is encapsulated.
22 . The composition of claim 19 wherein the GH95 alpha-L-fucosidase is encapsulated.
23 . The composition of claim 14 wherein the GH95 alpha-L-fucosidase and/or the direct fed microbial and/or the protease is administered to an animal as a feed or a premix.
24 . The composition of claim 19 wherein the GH95 alpha-L-fucosidase and/or the at least one direct fed microbial and/or the at least one protease are administered to an animal as a feed or a premix.
25 . The composition of claim 14 wherein the GH95 alpha-L-fucosidase is administered in a granule form.
26 . The composition of claim 19 wherein the GH95 alpha-L-fucosidase is administered in a granule form.